Timothy Zheng, PhD

Timothy S. Zheng joined Cygnal Therapeutics in June 2021 as Senior Vice President, Biology. For over two decades, Tim has dedicated his career to drug research and development, with a focus across immunology, fibrosis, and immuno-oncology. He has extensive experience spanning the entire spectrum of drug discovery and development, including target discovery, candidate nomination, and filing of investigational new drug applications (INDs) and biologics license applications (BLAs).

Tim joined Cygnal from Boehringer Ingelheim, where he was a Highly Distinguished Research Fellow. He also served as a Member of the U.S. Research Site Leadership Committee and as Executive Director, Immune Modulation. Prior to Boehringer Ingelheim, he held a number of roles at Biogen and Biogen Idec over a 17-year period with increasing responsibilities, most recently as Director of Immunology and then Director of Neuroimmunology. During his tenures at Biogen and Boehringer Ingelheim, Tim led many discovery research efforts that successfully transitioned to the development stage. He also managed external academic and industrial partnerships, as well as the evaluation of in-licensing programs.

Tim majored in nuclear chemistry during his undergraduate study at Fudan University in Shanghai, China and received his Ph.D. in immunology from Yale University. He holds several patents and has authored more than 50 papers. He regularly serves as a peer reviewer for scientific journals and speaks frequently at scientific conferences.

Timothy Zheng, PhD headshot

Cygnal is a best-in-class team of biomedical experts and leaders collaborating to revolutionize how the world treats diseases.